A high-level working group will explore legal pathways to market for certain CBD products, according to the US FDA – which also revealed it had sent warning letters to three companies it accused of “unfounded claims”
...
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
